睾酮治疗对合并多囊卵巢综合征的跨性别与性别多元人群的代谢影响
该研究回顾性分析373份病历,纳入62例按指南标准诊断多囊卵巢综合征(PCOS)的跨性别与性别多元(TGD)个体及132例年龄匹配的无PCOS者,比较睾酮治疗(TT)前后心血管危险因素(CVRF)变化。基线时合并PCOS者BMI、肥胖患病率更高;TT后组内变化无显著差异,控制BMI后仅高脂血症患病率、丙氨酸转氨酶(ALT)及生物可利用睾酮更高。
要点
- 合并PCOS的TGD个体基线心血管代谢风险较高,主要与BMI相关
- TT后组内变化在合并与不合并PCOS者间无显著差异
- 控制BMI后仅高脂血症与ALT升高在合并PCOS者中更常见
核心结论
- 合并PCOS的TGD个体基线心血管代谢风险更高,主要与BMI相关。
- 控制BMI后,TT期间仅高脂血症患病率和ALT升高在合并PCOS者中更常见。
- 研究支持对所有TGD个体在TT期间进行心血管代谢监测,PCOS病史未带来显著额外风险。
研究设计与样本
- 回顾性病历审查,共审查373份记录。
- 纳入62例符合指南标准的合并PCOS的TGD个体与132例年龄匹配的无PCOS的TGD个体。
- 收集TT前后的纵向人体测量、激素与代谢参数及CVRF数据。
- 组间比较采用独立t检验、Mann-Whitney U检验和卡方检验。
主要发现
- 基线时合并PCOS的TGD个体BMI、肥胖患病率显著更高。
- 控制BMI后,基线二甲双胍使用在合并PCOS者中显著更高。
- TT后组内变化在合并与不合并PCOS者间无显著差异。
- 控制BMI后,接受TT的合并PCOS者高脂血症患病率、ALT水平及生物可利用睾酮浓度显著高于无PCOS者。
临床怎么用
- 对接受TT的TGD个体应常规监测心血管代谢危险因素。
- 合并PCOS病史本身不构成额外风险分层依据,监测策略可一致。
- 对合并PCOS且接受TT者,控制BMI后仍需关注高脂血症与ALT升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic ovary syndrome (PCOS) affects 10% to 13% of individuals assigned female at birth (AFAB), although a greater prevalence is reported in transgender/gender diverse individuals (TGD) (23.8-38.8%). Testosterone therapy (TT) in TGD individuals is linked to worsening cardiovascular risk factors (CVRFs). Whether TT induces more adverse cardiometabolic changes in TGD with PCOS than TGD without PCOS remains uncertain. OBJECTIVE: To compare the effects of TT on CVRF in TGD with and without PCOS. METHODS: We retrospectively reviewed 373 records to identify 62 TGD with PCOS (withestablished guideline criteria) and 132 age-matched TGD without PCOS. Data included longitudinal anthropometric measurements, hormone and metabolic parameters, and CVRF before and after TT. Group comparison of PCOS vs without PCOS before and after TT was conducted via independent t-tests, Mann-Whitney-U, and Chi-square. RESULTS: At baseline, TGD with PCOS had significantly greater body mass index (BMI), obesity prevalence, and, after controlling for BMI, baseline metformin use. There were no significant differences between TGD with and without PCOS when comparing intra-participant changes after TT. Controlling for BMI, TGD with PCOS on TT exhibited significantly greater hyperlipidemia prevalence, alanine transaminase (ALT) levels, and bioavailable testosterone concentrations than TGD without PCOS on TT. CONCLUSION: Greater baseline cardiometabolic risk was largely BMI-related in TGD with PCOS compared to TGD without PCOS. Only hyperlipidemia and elevated ALT were more prevalent during TT after adjusting for BMI. These findings support cardiometabolic monitoring during TT in all TGD individuals without significant increased risk with PCOS history.
引用
- Herndon J, McNeil JA, Winter S, et al. Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome. J Clin Endocrinol Metab. 2026. PMID: 41606802. doi:10.1210/clinem/dgag032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。